NCT00777179 is a Phase 2 clinical trial of Vandetanib in NSCLC, sponsored by Genzyme, a Sanofi Company.

Who is sponsoring NCT00777179?

NCT00777179 is sponsored by Genzyme, a Sanofi Company.

What drugs are being tested in NCT00777179?

Interventions in NCT00777179: Vandetanib, Placebo.

Is NCT00777179 still recruiting?

NCT00777179 is currently completed. Last updated 29 August 2016.

Are results published for NCT00777179?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-08-29 · How we verify

NCT00777179

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized, Double-blinded, Placebo-controlled Phase II Study of Vandetanib (ZactimaTM) Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy

Completed Phase 2 Results posted Last updated 29 August 2016

What this trial tests

Phase 2 trial testing Vandetanib in NSCLC in 117 participants. Completed in 1 December 2011.

Timeline

1 October 2008

Primary endpoint
1 January 2010

1 December 2011

Quick facts

Lead sponsor	Genzyme, a Sanofi Company
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	117
Start date	1 October 2008
Primary completion	1 January 2010
Estimated completion	1 December 2011
Sites	5 locations across South Korea

Drugs / interventions tested

Vandetanib (VANDETANIB) — full drug profile →
Placebo

Conditions studied

NSCLC — all drugs for NSCLC →

Sponsor

Genzyme, a Sanofi Company — full company profile →

Who can join

18 and older, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Progression-free Survival (PFS) Rate at 3 Months
Time frame: 12 weeks
Progression-free survival (PFS) rate at 3 months is defined as the number of patients without evidence of progression or death after 3 months from randomisation among the PFS-evaluable patients.

Sponsor's own description

This study is multicenter, randomized, double-blinded, placebo-controlled Phase II study comparing vandetanib (300mg daily) plus best supportive care (BSC) to placebo plus BSC as maintenance treatment in patients with locally advanced or metastatic NSCLC, who have received and responded to prior platinum-doublet systemic chemotherapy. The primary objective of the study is to compare the Progression Free Survival (PFS) rate at 3 months in locally advanced or metastatic NSCLC patients with or without vandetanib maintenance.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials.
Wang Q, Huang H, Zeng X, Ma Y, et al · · 2016 · cited 9× · PMID 27781159 · DOI 10.7717/peerj.2550
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer.
Flanigan J, Deshpande H, Gettinger S. · · 2010 · cited 9× · PMID 20859451 · DOI 10.2147/btt.s7223

Verify or expand the search:

Other trials of Vandetanib

Trials testing the same drug.

NCT04760288 — A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). · Phase 3 · withdrawn
NCT06482086 — Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer · Phase 2 · recruiting
NCT03630120 — Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer · Phase 2 · terminated
NCT02495103 — Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Rena · Phase 1, PHASE2 · terminated
NCT01823068 — Vandetanib in Advanced NSCLC With RET Rearrangement · Phase 2 · completed

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Genzyme, a Sanofi Company trials

Trials by the same sponsor.

NCT06666413 — China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD · Phase 4 · recruiting
NCT05164055 — Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) · Phase 4 · active not recruiting
NCT05134571 — China Post-marketing Surveillance (PMS) Study of Aldurazyme® · Phase 4 · completed
NCT05054387 — China Post-marketing Surveillance (PMS) Study of Fabrazyme® · Phase 4 · completed
NCT04676373 — Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00777179 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genzyme, a Sanofi Company
Last refreshed: 29 August 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00777179.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing